|Bid||132.62 x 900|
|Ask||135.65 x 3200|
|Day's range||129.86 - 134.13|
|52-week range||86.43 - 142.64|
|Beta (5Y monthly)||1.39|
|PE ratio (TTM)||42.93|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Catalent's (CTLT) Biologics segment is likely to have maintained its momentum, thereby aiding Q1 results.
Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.
Catalent's (CTLT) new site is expected to become a key hub in its Asia-Pacific Clinical Supply Services network by significantly boosting its business.